Digital health is shifting focus from scientific innovation to logistical execution, with trends including a move from ex vivo to in vivo cell engineering, a shift in go-to-market strategies towards direct-to-clinician and direct-to-consumer models, and an anticipated wave of consolidation in the crowded AI healthcare market.
A key insight for you is the shifting focus from scientific to logistical challenges in biotech and digital health, highlighting an opportunity for technologies that enhance the delivery, affordability, and scalability of therapies. Specifically, the move from ex vivo to in vivo cell engineering approaches presents a potential breakthrough. This aligns with the broader trend of healthcare startups adopting direct-to-clinician and direct-to-consumer models, bypassing traditional procurement hurdles, and could be a critical area for investment and development to watch in 2026.